Bayer

This study looked at two drugs, darolutamide and enzalutamide, in men with prostate cancer that had returned after initial treatment but had not yet spread. The goal was to see how each drug affects testosterone levels and related side effects like breast tenderness. 28 men parti…

This study tested whether adding the drug darolutamide to standard hormone therapy (ADT) helps men with prostate cancer that has spread to other parts of the body. 669 men participated. The goal was to see if the combination could delay cancer growth and improve survival. Results…

This study tested a higher dose (8 mg) of the drug aflibercept in 892 people with macular edema (swelling) from a blocked retinal vein. The goal was to see if the higher dose works as well as the standard 2 mg dose but with fewer injections. Participants received injections every…

This study tested a new drug, BAY 3018250, to see if it can safely dissolve blood clots in people with deep vein thrombosis (DVT) in the leg. About 258 adults with recent DVT symptoms received either a high or low dose of the drug or a placebo. Researchers measured clot changes u…

This study tested whether the drug finerenone can slow the worsening of chronic kidney disease in people who do not have diabetes. About 1,580 adults took either finerenone or a placebo pill once a day, along with their usual kidney medications, for up to 50 months. Researchers m…

This study tested the drug larotrectinib in 215 adults with advanced solid tumors that have a specific change in the NTRK gene. The drug blocks the faulty gene's signals to stop cancer growth. The main goal was to see how many patients had their tumors shrink or disappear. Result…

This study tested a new drug called BAY 3283142 in over 1,200 adults with chronic kidney disease (CKD) who had high levels of a protein called albumin in their urine. The goal was to see if adding this drug to standard treatment could lower urine albumin better than a placebo. Pa…

This study tested whether the drug finerenone can slow the worsening of chronic kidney disease in people with type 1 diabetes. About 241 adults took either finerenone or a placebo pill for 6 months, along with their usual treatments. Researchers measured changes in urine protein …

This study collected data from 2,400 Chinese adults with chronic heart failure to see how well the drug vericiguat works compared to standard care. The main goal was to see if vericiguat could prevent death from heart problems or hospital stays due to heart failure. Researchers a…

This early-phase study tested a new drug called BAY 2862789 in 45 people with advanced solid tumors, including a type of lung cancer. The drug works by activating the body's immune T-cells to fight cancer. The main goals were to check safety, find the best dose, and see how the d…

This study followed 230 people with hemophilia A who were already prescribed Kovaltry to see how safe it is and how well it controls bleeding in everyday medical practice. Researchers tracked side effects and how many bleeds occurred. The goal was to gather real-world information…

This study gave long-term riociguat (Adempas) to 18 adults with pulmonary arterial hypertension who had already taken the drug in earlier Bayer trials. The main goal was to check safety and side effects over time. Patients stayed on the drug until it was no longer helpful or beca…

This study tested a new scoring method to help doctors choose the right dose of Jivi (a longer-lasting clotting factor) for people with hemophilia A. 21 participants switched from standard treatments to Jivi, and their dose plan was based on their personal risk score. The goal wa…

This study tested a new drug called BAY3283142 in 75 people with mild to moderate high blood pressure. The drug helps relax blood vessels and is being developed for chronic kidney disease. Participants took different doses or a placebo for up to 10 weeks to check for side effects…

This study looked at the safety of BAY 94-9027 (Jivi) in 36 children aged 7 to 12 with severe hemophilia A. The drug is a longer-lasting clotting factor that requires fewer injections. Researchers monitored for allergic reactions and whether the drug stopped working well during t…

This study tested the safety of aflibercept, an already-approved eye injection, in 100 Indian adults with diabetic macular edema (DME) — a condition where diabetes damages the retina and blurs vision. Participants received injections into the eye every 4 weeks for 5 months, then …

This study tested a new drug called larotrectinib in 75 adults with advanced solid tumors that have a specific gene change (NTRK fusion). The main goal was to check the drug's safety and find the best dose. Participants had cancers that stopped responding to other treatments or h…

This study tested whether a higher dose (8 mg) of the eye injection aflibercept, given every 16 weeks, works as well as the standard dose (2 mg) given every 8 weeks for Chinese people with diabetic macular edema (DME). DME causes vision problems due to swelling in the back of the…

This study tested a new contrast agent called gadoquatrane for MRI scans of the body (excluding the brain and spine). The goal was to see if a lower dose of gadolinium could still produce clear images compared to standard contrast agents. About 404 adults with known or suspected …

This study followed 1,500 women who chose to take different vitamin supplements before or during pregnancy. Researchers tracked pregnancy progress and outcomes like anemia, preeclampsia, and baby's birth weight. The goal was to gather more data on how vitamins affect pregnancy in…

This large phase 3 study tested whether asundexian, a new type of blood thinner, can prevent another ischemic stroke in people who recently had a stroke or mini-stroke. Over 12,000 adults took either asundexian or a placebo pill daily for up to 31 months, alongside their usual an…

This study tested a new medicine called elinzanetant for women who have hot flashes after menopause. Hot flashes are sudden feelings of heat and sweating that can disrupt daily life. The drug works by blocking a protein that triggers these flashes. In the study, 396 women took ei…

This study tested a tablet that sticks to the gum to treat cold sores (herpes labialis) in adults who get them often. About 2,020 participants used either the active tablet or a placebo at the first sign of a cold sore. The goal was to see if the tablet speeds up healing and redu…

This study tested a new drug called elinzanetant to see if it helps women sleep better during menopause. About 110 women with sleep problems took either the drug or a placebo for 12 weeks. Researchers measured how much time they spent awake at night using sleep tests.

This study tested whether starting the heart failure drug vericiguat at a 5 mg dose (instead of the usual 2.5 mg) is safe and tolerable for people with chronic heart failure with reduced ejection fraction. 106 participants took the 5 mg dose for 2 weeks. The goal was to see if sk…

This study tested a new medicine called elinzanetant to see if it can reduce hot flashes in women after menopause. About 400 women took either the drug or a placebo daily for up to 26 weeks. The researchers tracked how often and how severe the hot flashes were using an electronic…

This study looked at how much of the eye medicine aflibercept enters the bloodstream when given as injections into both eyes. It included 51 adults with diabetic macular edema or age-related macular degeneration. The goal was to measure drug levels in the blood, not to test if th…

This study looked at the order in which people with advanced bowel cancer (metastatic colorectal cancer) received two approved treatments: regorafenib and TAS (with or without bevacizumab). Researchers collected data from 121 patients in Europe to see how long each treatment sequ…

This study followed 100 babies who had been treated for retinopathy of prematurity (an eye problem in preterm infants) in an earlier study. Researchers measured their vision and checked for any eye problems over time. The goal was to understand the long-term safety and effectiven…

This study looked at medical records from over 5,700 adults in Japan who had sepsis (blood poisoning) to learn more about a serious complication called DIC, where blood clots form throughout the body. Researchers collected information on how many people developed DIC, how doctors…

This study looked at medical records of 818 adults with advanced colorectal cancer that had spread to other parts of the body. Researchers wanted to see what happens when patients take two approved drugs—regorafenib and TAS-102 (sometimes with bevacizumab)—in different orders. No…

This study looked at sleep problems in 750 women going through menopause. Researchers collected data from health records, questionnaires, and smartwatches to understand how often women wake up at night and how it affects their daily life. The goal was to learn more about these sl…

This study looked at 150 adults with sepsis in the ICU to find early warning signs in the blood that could predict a dangerous condition called DIC, where blood clots form throughout the body. Researchers checked for specific biomarkers and tracked patients for up to 56 days. No …

This study looked at data from 500 people in Germany who were prescribed vericiguat for chronic heart failure with reduced ejection fraction (a weak heart). Researchers wanted to see how well the drug works in everyday medical care, not just in a controlled trial. They measured d…

This study looked at medical records from nearly 5,000 Japanese adults with chronic heart failure who started taking vericiguat as part of their regular care. Researchers tracked hospital stays, deaths, and how well patients followed their treatment for up to one year. The goal w…

This study looked at how the drug radium-223 moves through bones in men whose prostate cancer has spread to the bone. About 60 men with at least 18 years of age took part, split into two groups based on how many bone tumors they had. They received up to 6 injections of radium-223…

This study looked at safety data from 1,500 people in Japan with peripheral artery disease (PAD) who had surgery to improve blood flow to their legs and were taking the blood thinner rivaroxaban. Researchers reviewed electronic health records to track bleeding events and heart-re…

This study looked at how well new pill forms of elinzanetant are absorbed by the body compared to the original soft gel capsule. Eighteen healthy women aged 18-65 took single and multiple doses of different pill versions. Researchers measured drug levels in the blood and checked …

This study looked at how moderate liver problems affect the way the body handles a new cancer medicine called sevabertinib. About 20 people (10 with liver impairment and 10 healthy) took a single dose and had their blood levels measured. The goal is to help doctors decide the rig…

This study looked at the long-term safety of Radium-223 in 1,472 men with metastatic castration-resistant prostate cancer. Researchers tracked side effects, bone marrow problems, and the risk of developing new cancers after treatment. The goal was to understand the drug's safety …